Maze Therapeutics (MAZE) Debt Ratio (2026)
Maze Therapeutics' (MAZE) quarterly Debt Ratio came in at 0.09 in Q1 2026.
Maze Therapeutics (MAZE) Debt Ratio (2026) Analysis & Trends
Maze Therapeutics has disclosed Debt Ratio across 1 years of filings, most recently posting 0.09 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 0.18 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Maze Therapeutics | 1.31 Bn | 1.31 Bn | 18.21 Mn | 0.09 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.09 |